JP6835472B2 - 癌の処置のための組成物 - Google Patents

癌の処置のための組成物 Download PDF

Info

Publication number
JP6835472B2
JP6835472B2 JP2015561618A JP2015561618A JP6835472B2 JP 6835472 B2 JP6835472 B2 JP 6835472B2 JP 2015561618 A JP2015561618 A JP 2015561618A JP 2015561618 A JP2015561618 A JP 2015561618A JP 6835472 B2 JP6835472 B2 JP 6835472B2
Authority
JP
Japan
Prior art keywords
cancer
another embodiment
inhibitor
combination
melanoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015561618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510748A5 (enExample
JP2016510748A (ja
Inventor
ジン ワン，
ジン ワン，
ジャンジュン チェン，
ジャンジュン チェン，
デュアン ディー． ミラー，
デュアン ディー． ミラー，
リ，　ウェイ
ウェイ リ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Publication of JP2016510748A publication Critical patent/JP2016510748A/ja
Publication of JP2016510748A5 publication Critical patent/JP2016510748A5/ja
Application granted granted Critical
Publication of JP6835472B2 publication Critical patent/JP6835472B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2015561618A 2013-03-05 2014-03-05 癌の処置のための組成物 Expired - Fee Related JP6835472B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361772885P 2013-03-05 2013-03-05
US61/772,885 2013-03-05
PCT/US2014/020858 WO2014138279A1 (en) 2013-03-05 2014-03-05 Compounds for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019017755A Division JP2019077727A (ja) 2013-03-05 2019-02-04 癌の処置のための組成物

Publications (3)

Publication Number Publication Date
JP2016510748A JP2016510748A (ja) 2016-04-11
JP2016510748A5 JP2016510748A5 (enExample) 2017-04-06
JP6835472B2 true JP6835472B2 (ja) 2021-02-24

Family

ID=51491914

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015561618A Expired - Fee Related JP6835472B2 (ja) 2013-03-05 2014-03-05 癌の処置のための組成物
JP2019017755A Pending JP2019077727A (ja) 2013-03-05 2019-02-04 癌の処置のための組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019017755A Pending JP2019077727A (ja) 2013-03-05 2019-02-04 癌の処置のための組成物

Country Status (11)

Country Link
US (2) US10022356B2 (enExample)
EP (1) EP2964028A4 (enExample)
JP (2) JP6835472B2 (enExample)
KR (1) KR102246652B1 (enExample)
CN (2) CN105163584B (enExample)
AU (2) AU2014225761B2 (enExample)
CA (1) CA2904338C (enExample)
IL (1) IL241232B (enExample)
MX (2) MX375059B (enExample)
RU (1) RU2708247C2 (enExample)
WO (1) WO2014138279A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) * 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
DK2303021T3 (en) * 2008-06-16 2019-04-08 Univ Tennessee Res Found RELATIONSHIPS FOR TREATING CANCER
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
CN105163584B (zh) * 2013-03-05 2019-06-04 田纳西大学研究基金会 用于治疗癌症的化合物
RU2733393C9 (ru) 2014-05-06 2021-09-09 Джи Ти Икс, ИНК. Соединения для лечения рака
CN104434924B (zh) * 2014-11-10 2016-09-14 暨南大学 曲美替尼在制备逆转肿瘤多药耐药性药物中的应用
WO2016106359A1 (en) * 2014-12-23 2016-06-30 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and taxanes
EP3256473A4 (en) 2015-02-12 2018-08-01 Memorial Sloan Kettering Cancer Center Synergistic cancer treatment
WO2016197129A1 (en) * 2015-06-05 2016-12-08 The Board Of Trustees Of The University Of Illinois Pac-1 combination therapy
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
CA2991777A1 (en) * 2015-07-09 2017-01-12 The Jackson Laboratory Methods of treating cancer by administering a mek inhibitor in combination with a proteasome inhibitor
US20180228740A1 (en) * 2015-08-06 2018-08-16 The Wistar Institute Of Anatomy And Biology Combination therapies targeting mitochondrial biogenesis for cancer therapy
AU2017232496B2 (en) 2016-03-16 2022-11-24 Dicerna Pharmaceuticals, Inc. Compositions and methods for the treatment of a beta-catenin-associated disease or disorder
WO2017200826A1 (en) * 2016-05-16 2017-11-23 Albert Einstein College Of Medicine, Inc. Assays and compounds for treatment of cancer
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
US12339285B2 (en) 2017-03-10 2025-06-24 Konica Minolta, Inc. Method for estimating therapeutic efficacy
JP7291399B2 (ja) * 2017-05-03 2023-06-15 ティン セラピューティクス エルエルシー 難聴の予防および治療のための組成物および方法
IL274663B2 (en) 2017-11-17 2024-01-01 Univ Illinois Cancer therapy by degrading dual mek signaling
CN108218855A (zh) * 2018-03-12 2018-06-29 桑文军 一种新型微管蛋白抑制剂及其在抗肿瘤药物中的应用
CN112437664A (zh) * 2018-05-15 2021-03-02 田纳西大学研究基金会 用于治疗胰腺癌的化合物
AU2019270089B2 (en) * 2018-05-15 2022-11-10 University Of Tennessee Research Foundation Compounds for treatment of triple negative breast cancer and ovarian cancer
CA3114385A1 (en) 2018-10-05 2020-04-09 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma
GB201913124D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
MX2022009347A (es) * 2020-01-31 2022-12-15 Verastem Inc Terapia de combinacion para el tratamiento del crecimiento celular anormal.
CN113440616A (zh) * 2020-03-25 2021-09-28 上海科州药物研发有限公司 Ras或raf突变型癌症的联合疗法
WO2022006512A1 (en) * 2020-07-02 2022-01-06 The Board Of Regents Of The University Of Texas System Methods of treatment for melanoma
WO2022067185A1 (en) * 2020-09-27 2022-03-31 Veru Inc. Methods of treating prostate cancer with minimal side effects
WO2022131667A1 (ko) * 2020-12-18 2022-06-23 경희대학교 산학협력단 Oligodendrocyte transcription factor 2 억제제를 유효성분으로 포함하는 흑색종 치료 효과 증진용 약학적 조성물
CN115504964A (zh) * 2022-04-12 2022-12-23 海创药业股份有限公司 氘代杂环酮类化合物及其用途
CN117143081B (zh) * 2022-05-24 2025-08-01 赣南医科大学 一种Sabizabulin的制备方法
US20260115209A1 (en) * 2022-08-08 2026-04-30 The Regents Of The University Of California Combination therapy including cox-2 inhibitor for the treatment of cancer
WO2024186641A1 (en) * 2023-03-03 2024-09-12 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
US20250032788A1 (en) * 2023-06-30 2025-01-30 Novocure Gmbh Compositions and methods for treating with a combination of alternating electric fields and dna-dependent protein kinase inhibitors
CN119409641A (zh) * 2024-11-05 2025-02-11 杭州电子科技大学 一种磺酰基衍生物和用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
CA2074933C (en) 1990-11-30 2002-12-03 Masatoshi Chihiro Thiazole derivatives as active superoxide radical inhibitors
US5120749A (en) 1991-02-20 1992-06-09 Abbott Laboratories Platelet activating antagonists
JP2550915B2 (ja) 1994-06-21 1996-11-06 日本電気株式会社 印刷配線板の表面保護剤および表面保護膜の形成方法
AU3113902A (en) 2000-12-21 2002-07-01 Bristol Myers Squibb Co Thiazolyl inhibitors of tec family tyrosine kinases
US20040267017A1 (en) 2001-09-26 2004-12-30 Bierer Donald E 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors
WO2003027094A2 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
EP1456187A4 (en) 2001-11-15 2005-02-09 Incyte San Diego Inc N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTERINEMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDER, CANCER AND OTHER DISEASES
JP2006518738A (ja) 2003-02-12 2006-08-17 トランス　テック　ファーマ，インコーポレイテッド 治療薬としての置換アゾール誘導体
DE602004006852D1 (de) 2003-04-17 2007-07-19 Janssen Pharmaceutica Nv 2-phenyl-benzimidazol und 2-phenyl-imidazo-4,5ü-pyridin-derivate als checkpoint-kinase-cds1 (chk2)-hemmer zur behandlung von krebs
WO2004110998A1 (en) 2003-05-16 2004-12-23 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
AU2004291539A1 (en) 2003-11-18 2005-06-02 Ohio State University Research Foundation Thiazolidinone amides, thiazolidine carboxylic acid amides, methods of making, and uses thereof
PE20050676A1 (es) 2003-12-12 2005-11-02 Wyeth Corp Quinolinas referidas a enfermedades cardiovasculares
JP2007527917A (ja) 2004-03-08 2007-10-04 ワイス イオンチャンネルモジュレーター
EP2298292A3 (en) 2004-06-18 2011-08-10 Agennix USA Inc. Kinase inhibitors for treating cancers
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
DK2395004T3 (en) * 2005-06-22 2016-03-21 Plexxikon Inc Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors
US7612212B2 (en) * 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
JPWO2007132867A1 (ja) 2006-05-15 2009-09-24 杉本　芳一 癌の予防及び治療剤
US7464893B2 (en) * 2006-06-30 2008-12-16 Per Spjut Method of using a cord holder
KR100932093B1 (ko) 2006-09-27 2009-12-16 주식회사종근당 미세소관 형성 저해제로서 유용한 벤조페논 유도체
DK2303021T3 (en) 2008-06-16 2019-04-08 Univ Tennessee Res Found RELATIONSHIPS FOR TREATING CANCER
US9029408B2 (en) * 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US8822513B2 (en) * 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) * 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
DK4397376T3 (da) 2009-10-16 2026-02-23 Novartis Ag Kombination der omfatter en mek-hæmmer og en b-raf-hæmmer
KR101939704B1 (ko) * 2010-03-01 2019-01-17 지티엑스, 인코포레이티드 암 치료용 화합물
WO2012027716A1 (en) * 2010-08-27 2012-03-01 Collabrx, Inc. Method to treat melanoma in braf inhibitor-resistant subjects
CN103443725B (zh) 2011-03-29 2015-07-29 三菱电机株式会社 伺服控制装置的异常诊断装置及异常诊断系统
ES2620644T3 (es) 2011-04-01 2017-06-29 Genentech, Inc. Combinaciones de compuestos inhibidores de AKT y agentes quimioterapéuticos, y métodos de uso
EA024890B1 (ru) 2011-04-07 2016-10-31 Байер Интеллектчуал Проперти Гмбх Имидазопиридазины в качестве ингибиторов akt киназы
CN105163584B (zh) 2013-03-05 2019-06-04 田纳西大学研究基金会 用于治疗癌症的化合物

Also Published As

Publication number Publication date
RU2015142102A3 (enExample) 2018-03-13
CN109568312A (zh) 2019-04-05
RU2015142102A (ru) 2017-04-07
JP2016510748A (ja) 2016-04-11
RU2708247C2 (ru) 2019-12-05
MX375059B (es) 2025-03-06
EP2964028A1 (en) 2016-01-13
US10525037B2 (en) 2020-01-07
JP2019077727A (ja) 2019-05-23
AU2014225761A1 (en) 2015-10-08
KR102246652B1 (ko) 2021-04-29
CN105163584B (zh) 2019-06-04
KR20150123328A (ko) 2015-11-03
EP2964028A4 (en) 2017-06-07
MX2020009256A (es) 2020-10-28
WO2014138279A1 (en) 2014-09-12
US10022356B2 (en) 2018-07-17
CA2904338A1 (en) 2014-09-12
CA2904338C (en) 2022-07-05
IL241232A0 (en) 2015-11-30
MX2015011713A (es) 2016-05-09
IL241232B (en) 2021-02-28
US20180325872A1 (en) 2018-11-15
AU2018226470B2 (en) 2019-11-28
AU2014225761B2 (en) 2018-06-07
US20160015688A1 (en) 2016-01-21
CN105163584A (zh) 2015-12-16
AU2018226470A1 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
JP2019077727A (ja) 癌の処置のための組成物
JP6180420B2 (ja) 増殖性疾患の治療のためのｈｓｐ９０阻害剤と組み合わせた２−カルボキサミドシクロアミノウレア誘導体
CA2953079C (en) Intermittent dosing of mdm2 inhibitor
TW201728583A (zh) 氨基噻唑化合物及其用途
JPWO2008001886A1 (ja) オーロラ（Ａｕｒｏｒａ）阻害剤
KR102382771B1 (ko) 증식성 질환을 위한 조합 치료
JP2021100972A (ja) がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
TWI434680B (zh) 二萜類化合物於治療攝護腺癌之用途
JP2019508457A (ja) 増殖性疾病の組み合せ療法
JP2015510945A (ja) オーロラキナーゼ阻害薬を使用する癌の治療方法
US10512631B2 (en) Chalcone compounds
US11389434B2 (en) Methods and pharmaceutical compositions for the treatment of mast cell diseases
HK40005718A (en) Compounds for treatment of cancer
CN121013721A (zh) 包含kras抑制剂和sph2抑制剂的组合疗法
CN101198253A (zh) 治疗癌症的组合、方法和组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180423

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190204

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190204

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20190227

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190408

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20190409

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20190517

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20190521

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20190827

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20191011

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200515

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200702

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201009

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201120

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20201225

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210120

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210204

R150 Certificate of patent or registration of utility model

Ref document number: 6835472

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees